GT Biopharma, Inc.

Healthcare · Biotechnology · United States

Last price 5.6 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 10.10M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product cand...